More Cambium Bio Ltd news
Cambium Bio LtdASX: CMB

FY25 Appendix 4E and Annual Report

Aug 29, 2025 at 6:17 AM EDT · Issued by Cambium Bio Ltd

Filed with ASX · Aug 29, 2025 at 6:17 AM EDT

On 6ix: 6ix.com/news/fy25-appendix-4e-and-annual-report-20

Cambium Bio Limited has released a press release.

View Attachment

6ix hasn’t read this filing yet.

Cambium Bio Ltd on 6ix

Story so far

  • Appendix 4E - Preliminary final report-unauditedAug 31, 2023

Earlier from Cambium Bio

  • Placement Participant UpdateAug 27, 2025
  • Cambium Bio Raises A$2.12 millionJul 30, 2025
  • Half Year Report (December 2024)Cambium Bio Limited Half Year Report (December 2024) (Feb 27, 2025Feb 27, 2025)Feb 27, 2025
  • FDA Approves Elate Ocular Phase 3 Clinical Trial ProtocolFeb 24, 2025
  • Cambium Bio Successfully Closes A$3.0M Financing RoundDec 4, 2024

Later from Cambium Bio

  • Cambium Bio Signs US$2.0M plus Licensing DealSep 2, 2025
  • Cambium Bio Signs Strategic MoU with Benta SASSep 5, 2025
  • Cambium Bio Secures A$2.4 Million Strategic InvestmentJan 19
  • Quarterly Activities/Appendix 4C Cash Flow ReportJan 22
  • Half Year Report and AccountsFeb 19
All Cambium Bio news releases↗

Follow Cambium Bio into a list and get an email when it puts out news.

Follow Cambium Bio
  • About 6ix
  • Editorial & Sourcing
  • Corrections
  • Contact
  • Privacy
  • Terms
  • Disclaimer